Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

TORM plc interim results for the half-year ended 30 June 2017

"I am satisfied that we have been able to deliver a profit for the first six months of 2017 despite a difficult product tanker market. Over the summer, we have utilized our strong capital structure to pursue two attractive vessel growth opportunities totaling six vessels at what we believe is an opportune time in the cycle," says Executive Director Jacob Meldgaard. In the first six months of 2017, TORM realized a positive EBITDA of USD 80m and a profit before tax of USD 3m. Q2 2017 had an EBITDA of USD 36m and a profit before tax of USD         -2m. · EBITDA for the half-year ended

Tieto’s financial calendar 2018

Tieto Corporation   STOCK EXCHANGE RELEASE   16 August 2017, 10.00 am EET 6 February Interim report 4/2017 and financial  statements bulletin for 2017 (8.00 am EET)By 28 Annual Report 2017 on Tieto's websiteFebruary22 March Annual General Meeting Tieto will publish three interim reports in 2018: 26 April Interim report 1/2018 (8.00 am EET)20 July Interim report 2/2018 (8.00 am EET)24 October   Interim report 3/2018 (8.00 am EET) For further information, please contactTanja Lounevirta, Head of Investor Relations, tel.

Saab delivers training systems to Estonian Army

Defence and security company Saab has signed a contract with the Estonian Armed Forces to deliver BT46 training systems to the Estonian Army. The deliveries will be made in 2018.The Estonian Armed Forces ordered the first laser simulators for gunnery and combat training in 2008. Saab has now received an additional order for simulators. The systems will be used by the mechanised brigade, at the regiments and at the infantry school. “I am proud that the Estonian Armed Forces have once again chosen Saab as their partner. They have used our training systems for quite some time and are very

SOTKAMO SILVER IS IN ADVANCED DISCUSSIONS ABOUT THE FINANCING OF THE SILVER MINE

Sotkamo Silver is in advanced discussions with a large international resources financing institution and the Swedish Export Credit Agency (ECA) for a comprehensive financing package, to fund the Engineering and Process Equipment (EPC) contract with Outotec and enable the mine to reach the production start. The discussions concerning terms and conditions are dependent on the guarantee decision of The Swedish Export Credit Agency (ECA). The discussions do not constitute a commitment or an offer to commit to any transaction or financing. The next step is the guarantee decision of the

Episurf Medical reaches milestone of 250 implants

Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by planning of its 250th surgery with the Episealer® implant in the coming weeks. “This milestone is very important for us, and at the same time, it is important to keep in mind that our clinical data is very strong and the patients are truly being helped by our technology. That said, it is obviously very encouraging that we have cut the time between our 50 intervals in half. Increasing our sales is important and this is a clear sign of the fact that the Episealer technology is gaining

Photocure files supplemental New Drug Application with FDA for Blue Light Cystoscopy (BLC(TM)) with Cysview®

Oslo, Norway, August 16[th] Photocure ASA (OSE: PHO) announced today that it has filed a supplemental new drug application (sNDA) with the U.S. Food and Drug Administration (FDA) for BLC[(TM) ]with Cysview[®] for use during surveillance cystoscopy to detect recurrence of bladder cancer using a flexible cystoscope. The filing is a combination drug device application with the KARL STORZ D-LIGHT C PDD Flexible Videoscope System. The sNDA also supports the approval for repeated use of BLC with Cysview and to expand the indication include detection of carcinoma in situ (CIS). BLC with Cysview

Biotage – alleged patent infringement settled

Scientific Plastic Products, Inc. (“SPP”) has brought claims for infringement of U.S. Patent Nos. 8,066,875 and 8,070,957, against Biotage et alt. in a civil action entitled Scientific Plastic Products, Inc. v. Biotage AB, et al. (“Defendants”), pending in the United States District Court for the Southern District of California (the “Lawsuit”). The matter has been amicably resolved and the Lawsuit has been dismissed. Defendants have not agreed to any liability and no claim remains pending against Defendants. The terms of settlement are confidential. Contact persons:Torben Jörgensen,

Rabbalshede Kraft signs service and maintenance agreement with Vänern wind farm

Rabbalshede Kraft has signed a three-year management agreement with Vänern wind farm. Rabbalshede will be responsible for the management, monitoring, servicing and maintenance of seven of the wind turbines of Vänerns wind farm. The agreement extends over three years with the possibility of two years extension. For service and maintenance, Rabbalshede Kraft has signed a partnership agreement with Monsson Nordic AB.The wind farm, consisting of WinWind 3 MW turbines, is located on Gässlingegrundet in northern Vänern. The turbines that Rabbalshede Kraft will manage is owned by Vindpark Vänern

FDA accepts Medivir´s IND application for MIV-711, enabling clinical development in the US

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today that the Investigational New Drug (IND) application for MIV-711 has been accepted and the IND is now open with the FDA (U.S. Food and Drug Administration). “We are very pleased to have received FDA acceptance for our IND. This is a regulatory milestone for MIV-711 and enables clinical development of MIV-711 in the US, in addition to the already completed and ongoing studies in Europe” says Åsa Holmgren, Medivir´s EVP Strategic Regulatory Affairs and Market Access. About MIV-711MIV-711 is being developed to slow

C-RAD AB - Interim report April-June 2017

Key events in the period April - June 2017   SECOND QUARTER 2017                                                 ·       Net sales: 32.2 (15.6) MSEK, +106%. ·       Order intake: 49.3 (30.4) MSEK, +62%. ·       EBITDA: -2.7 (-8.3) MSEK. ·       Operating loss: -4.1 (-9.8) MSEK. ·       Result per share -0.14 (-0.44) SEK. ·       Agreement with Miami Cancer Institute, 7.5 MSEK. ·       Agreement with two cancer centers in France, 9 MSEK. ·       Positive verdict in patent case with Beamocular.    Comments from Tim Thurn, CEO:   C-RAD´s growth

Invitation to presentation of AcadeMedia's full year result for July - June 2016/17

AcadeMedia's full year result for July - June 2016/17 will be published at 08:00 CET on August 30. A web-cast telephone conference will be held at 09:30 CET the same day, where CEO Marcus Strömberg and CFO Eola Änggård Runsten will present the report. The presentation will be held in English and can be followed on the web or over the phone. It will be followed by a Q&A session. To participate in the conference call, and thereby be able to ask questions, call one of the following numbers ten minutes before the start of the call: SE: +46 8 5664 2690UK: +44 20 3008 9801US: +1 855

Management changes at Handelsbanken

Hannu Saari has been appointed as the head of a new department which will have overall Group-wide responsibility for all Handelsbanken’s measures to counteract financial crime. He is currently Head of Handelsbanken’s operations in Luxembourg and France. Hannu Saari will take up his new position on 1 September 2017, and will also be a member of the Bank’s Senior Management.  For further information, please contact:  Anders Bouvin, President and Group Chief Executive, +46 8–22 92 20Stefan Nilsson, Acting Chief Communications Officer, +46 8–701 89 04,+46 70–225 91 04Johan

Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin®

Isofol Medical AB (publ) announces that Professor Sten Nilsson, an experienced industry advisor and principal investigator, and Dr. Alain Herrera, a seasoned industry executive, has joined Isofol as advisors to its Board of Directors.Isofol Medical AB (publ), a clinical stage oncology company, announces that a cooperation has been established with Professor Sten Nilsson and Doctor Alain Herrera who have joined Isofol as advisors to its Board of Directors. In addition to several of the World’s leading oncologists being part of Isofol’s Advisory Board this strengthens the company with

ROTTNEROS INTERIM REPORT JANUARY – JUNE 2017

STRONG QUARTER WITH HIGH PRODUCTION AND GOOD PERFORMANCE· Production volume for the second quarter rose by 1% compared with the second quarter of 2016, despite the unplanned shutdown at Vallvik Mill, which entailed a production loss of about 4,500 tonnes. Rottneros Mill set a new quarterly production record once again. · Delivery volume for the second quarter rose by 7% compared with second quarter 2016. · Investments in the Agenda 500 development programme are progressing according to plan, in terms of both cost and increased capacity. · Rottneros Packaging is starting commercial

Swedbank acquisition of PayEx is approved by competition authorities and Swedish FSA

The Swedbank acquisition of PayEx is now approved by the competition authorities in Sweden and Norway and by the Swedish FSA. With the approvals in place, Swedbank has completed the acquisition of PayEx, and PayEx is now a fully owned subsidiary to Swedbank.The market for payment solutions has undergone major changes in recent years by greatly increased on-line purchases and development of invoicing solutions and administrative services. Payment Service Providers (PSP), as PayEx, has been established with the purpose to improve the purchase experience. Through the approval of the

KID ASA – SECOND QUARTER 2017 RESULTS

Lier, 16 August 2017: The board of directors of Kid ASA has approved the financial report for the second quarter of 2017. Q2 HIGHLIGHTS (Figures from corresponding period the previous year in brackets) · Revenues of MNOK 278.4 (MNOK 265.5) in Q2 2017, an increase of 4.9%. Revenues were negatively affected by the timing of the Easter holiday in Q2 this year, whereas Easter was in Q1 last year. For the first two quarters of 2017, revenues amounted to MNOK 532.3 (MNOK 496.0), up 7.3% from 2016. The number of ordinary shopping days in the second quarter was 71 (75), and for the two

Nokian Tyres plc: Shares subscribed with option rights

Nokian Tyres plc Stock Exchange Release August 16, 2017, 9.00 a.m. After May 11, 2017 registered new shares a total of 693,053 Nokian Tyres plc's shares have been subscribed with the 2013A option rights, a total of 7,062 shares with the 2013B option rights and a total of 52,026 shares with the 2013C option rights. These option rights are attached to the Nokian Tyres plc's Option Program of 2013. New shares have been registered into the Trade Register on August 16, 2017, as of which date the new shares will establish shareholder rights. The share capital will not increase with

INCREASED SALES AND FURTHER FOCUSING OF BUSINESS OPERATION

Sales in the remaining operation, Fingerprint Technology, increased during the quarter. The partnership with Silead has resulted in substantial royalty revenues as Precise BioMatch Mobile has been launched in a number of phone models from one of the world’s biggest manufacturers. Precise Biometrics concluded an agreement with IDENTOS to divest the Mobile Smart Card Solutions business area in order to focus its activities on the Fingerprint Technology business area.SECOND QUARTER  · Net sales for the remaining operation totaled SEK 20.2 (18.9) million. · The operating profit for

NATTO: 2017 Half Year Earnings Release

Please find attached the Nattopharma Group 2017 Half Year Earnings Release. Financial highlights for the First Half of 2017 are;   · Revenue rose by 18,6% to NOK 30,6 million · Gross Margin for the period was 45,8 %, · Positive adjusted EBITDA of NOK 1,5 million for the supplement business A presentation will be held via webcast by CEO Daniel H. Rosenbaum and CFO Kjetil Ramsøy at 10 am CET, Wednesday 16th August 2017, followed by a Q&A session directly thereafter. Please follow the below link to join the webcast; http://webtv.hegnar.no/presentation.php?

LeoVegas Q2 2017: Steady growth with profitability and strong start to Q3

"As the first gaming company, we now choose to break out revenue from Sweden. Sweden accounts for 37 percent which amounts to EUR 18 million in the second quarter. It puts us in the driver's seat before the coming regulation. The amazing development in Denmark continues and the UK has also had an impressive quarter. This gives us strong momentum into the third quarter, where July started very well with NGR at the new record level of EUR 18.3 million"Gustaf Hagman, Group CEO and co-founder Second quarter: 1 April-30 June 2017[1] · Revenue increased by 60% to EUR 49.7 m (31.0).

SHARE OPTION GRANT TO CORPORATE MANAGEMENT TEAM

As previously announced, Techstep ASA (“Company” or “Techstep”) has strengthened its corporate management team by appointing Erik Haugen as the Company’s Chief Commercial Officer (CCO) and Inge Paulsen as the Company’s Chief Operating Officer (COO). Erik Haugen will assume its position as the Company’s CCO as of 1 October 2017, while Inge Paulsen has served as the Company’s COO since May 2017. Through Erik Haugen’s and Inge Paulsen’s positions as key employees and members of the corporate management team of Techstep, the Board of Directors in Techstep has today granted 1 million share

Milestone quarter, new markets opened up

Zalaris' Q2/17 revenues were up 33.2% to NOK 126.9 million (incl. sumarum AG which was acquired in the quarter and included from 18 May), with an EBIT margin of 5.7%. First half-2017 pro forma revenues for the combined entity are 15.4% higher compared to the same period in 2016.Zalaris, a leading provider of payroll and HR services, announced mid-May the acquisition of sumarum AG. Through the acquisition, Zalaris is gaining an immediate access into Germany, Europe’s largest economy with more than 80 million people and a high concentration of medium-size and large international companies.

MenaQ7® Vitamin K2 Again Shown to Inhibit Hardening of Arteries: New Study

Clinical single-arm trial with renal transplant recipients shows improved arterial stiffnessOSLO, NORWAY and METUCHEN, NJ (August 16th, 2017) – A new study1 of renal transplant recipients, a group shown to express subclinical vitamin K deficiency, examined whether K2 supplementation would correct this deficiency and thus improve arterial stiffness. The study has published in Journal of the American Society of Hypertension, and the vitamin K2 used in the study was MenaQ7® Vitamin K2 as MK-7 from NattoPharma. This Lebanese study evaluated in the KING trial (a single-arm pilot study) to see

There are no items matching the current filter
There are no more items matching the current filter
Back to top